Decreased hypothalamic glucagon-like peptide-1 receptor expression in type 2 diabetes patients

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 5, 2016, Pages 2122-2129

  Ten Kulve, Jennifer S ^a   Van Bloemendaal, Liselotte ^a   Balesar, Rawien ^b   Ijzerman, Richard G ^a   Swaab, Dick F ^c   Diamant, Michaela ^a   La Fleur, Susanne E ^b   Alkemade, Anneke ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI RELATED PROTEIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; MESSENGER RNA; NEUROPEPTIDE Y; PROOPIOMELANOCORTIN; AGRP PROTEIN, HUMAN;

ADULT; AGED; ARCUATE NUCLEUS; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENERGY METABOLISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; GENETICS; HYPOTHALAMUS; METABOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGOUTI-RELATED PROTEIN; ARCUATE NUCLEUS OF HYPOTHALAMUS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOTHALAMUS; MALE; MIDDLE AGED; NEUROPEPTIDE Y; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PRO-OPIOMELANOCORTIN;

EID: 84969895370     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3291     Document Type: Article

References (28)

1. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-165.
2. Flint A, Raben A, Astrup A, Holst JJ.Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515-520.
3. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab. 2001;86(9):4382-4389.
4. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
5. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.
6. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-837.
7. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience. 1997;77(1):257-270.
8. Blevins JE, Baskin DG. Hypothalamic-brainstem circuits controlling eating. Forum Nutr. 2010;63:133-140.
9. Shugrue PJ, Lane M, Merchenthaler I. Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology. 1996;137:5159-5162.
10. Heppner KM, Kirigiti M, Secher A, et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology. 2015;156(1):255-267.
11. Williams DL. Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. Endocrinology. 2009;150(7):2997-3001.
12. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes. 2008;57(8):2046-2054.
13. McMahon LR, Wellman PJ. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am J Physiol. 1998;274(1 Pt 2):R23-R29.
14. Alvarez E, Martinez MD, Roncero I, et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem. 2005;92(4):798-806.
15. Alkemade A, Yi CX, Pei L, et al. AgRP and NPY expression in the human hypothalamic infundibular nucleus correlate with body mass index, whereas changes in αMSH are related to type 2 diabetes. J Clin Endocrinol Metab. 2012;97(6):E925-E933.
16. Kubota K, Ohashi A, Imachi H, Harada H. Improved in situ hybridization efficiency with locked-nucleic-acid-incorporated DNA probes. Appl Environ Microbiol. 2006;72(8):5311-5317.
17. Siljee JE, Unmehopa UA, Kalsbeek A, Swaab DF, Fliers E, Alkemade A. Melanocortin 4 receptor distribution in the human hypothalamus. Eur J Endocrinol. 2013;168(3):361-369.
18. Goldstone AP, Unmehopa UA, Bloom SR, Swaab DF. Hypothalamic NPY and agouti-related protein are increased in human illness but not in Prader-Willi syndrome and other obese subjects. J Clin Endocrinol Metab. 2002;87(2):927-937.
19. Swaab DF, Visser M. A function for alpha-MSH in fetal development and the presence of an α-MSH-like compound in nervous tissue. Front Horm Res. 1977;4:170-178.
20. Hestiantoro A, Swaab DF. Changes in estrogen receptor-α and -β in the infundibular nucleus of the human hypothalamus are related to the occurrence of Alzheimer's disease neuropathology. J Clin Endocrinol Metab. 2004;89(4):1912-1925.
21. Borgers AJ, Koopman KE, Bisschop PH, et al. Decreased serotonin transporter immunoreactivity in the human hypothalamic infundibular nucleus of overweight subjects. Front Neurosci. 2014;8:106.
22. Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes. 1998;47(4):530-537.
23. Xu G, Kaneto H, Laybutt DR, et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes. 2007;56(6):1551-1558.
24. Ma X, Bruning J, Ashcroft FM. Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J Neurosci. 2007;27(27):7125-7129.
25. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473-4488.
26. Yang Y, Moghadam AA, Cordner ZA, Liang NC, Moran TH. Long term exendin-4 treatment reduces food intake and body weight and alters expression of brain homeostatic and reward markers. Endocrinology. 2014;155(9):3473-3483.
27. van der Stouwe JG, Aeschbacher S, Krisai P, et al. Plasma levels of glucagon-like peptide 1 and markers of obesity among young and healthy adults. Clin Endocrinol (Oxf). 2015;83(5):636-642.
28. Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia. 2011;54(2):339-349.